Results 71 to 80 of about 20,950 (257)

Unravelling the Major Cardiovascular Risks of Systemic Psoriasis Medications: A Literature Systematic Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Psoriasis is a chronic inflammatory dermatological condition associated with an elevated risk of cardiovascular events (CVEs). Systemic therapies have transformed disease management, but their cardiovascular (CV) safety profiles remain incompletely understood and inconsistently reported.
Mai Thi Hoai Son, Yves Julien Mbama Biloa, Pauline Gouttefarde, Thomas Franck, Gilles Cizeron, Mathieu Oriol, François Maccari, Elisa Cinotti, Beatrice Trombert‐Paviot, Bienvenu Bongue, Jean‐Luc Perrot   +10 more
wiley   +1 more source

Characteristics of Adult Patients With Atopic Dermatitis Initiating Biologics and Janus Kinase Inhibitors in the CorEvitas Atopic Dermatitis Registry

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Biologics and Janus kinase inhibitors (JAKi) are two advanced systemic treatment options for patients with atopic dermatitis (AD). The decision to initiate one of these therapies is complex and may be driven by many factors.
Eric L. Simpson, Linda Stein Gold, Seemal R. Desai, Alexandra K. Golant, Douglas DiRuggiero, Christian Fenske, Yolanda Muñoz Maldonado, Alvin H. Li, Zach Dawson, Kaylee Ho, Kayla Callahan, Gaia Gallo, Jonathan I. Silverberg   +12 more
wiley   +1 more source

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study

Arthritis Research & Therapy, 2018
Background Secukinumab has demonstrated sustained improvement in the signs and symptoms of psoriatic arthritis (PsA) over 2 years in the FUTURE 2 study (NCT01752634).
L. C. Coates, D. D. Gladman, P. Nash, O. FitzGerald, A. Kavanaugh, T. K. Kvien, L. Gossec, V. Strand, L. Rasouliyan, L. Pricop, K. Ding, S. M. Jugl, C. Gaillez, on behalf of the FUTURE 2 study group   +13 more
doaj   +1 more source

Effects of secukinumab and ixekizumab on major adverse cardiovascular events in patients with psoriasis: a meta-analysis of randomized controlled trials

Frontiers in Medicine
Introduction The aims of this study is to analyze the risk of major adverse cardiovascular events (MACEs) in patients with psoriasis treated with secukinumab and ixekizumab.
Yonghong Zhang, Zhiya Yang, Jinyan Gong, Dongmei Shi   +3 more
semanticscholar   +1 more source

Investigation of plaque psoriasis relapse after secukinumab withdrawal in patients from two Phase 3 studies.

Clincal and Experimental Dermatology, 2023
BACKGROUND Secukinumab is effective against a range of psoriatic manifestations. Investigating psoriasis (PsO) relapse following secukinumab discontinuation could provide insights into long-term PsO remission.
M. Lebwohl, L. Iversen, L. Eidsmo, James G. Krueger, M. Suárez-Fariñas, Lewis E. Tomalin, F. Kolbinger, R. You, M. Milutinovic   +8 more
semanticscholar   +1 more source

Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT

Arthritis Research & Therapy, 2021
Background To investigate the efficacy of secukinumab in patients with active non-radiographic axial spondyloarthritis (nr-axSpA) grouped by disease activity as assessed by C-reactive protein (CRP) levels and/or magnetic resonance imaging (MRI) scores ...
Jürgen Braun, Ricardo Blanco, Helena Marzo-Ortega, Lianne S. Gensler, Filip van den Bosch, Stephen Hall, Hideto Kameda, Denis Poddubnyy, Marleen van de Sande, Anna S. Wiksten, Brian O. Porter, Abhijit Shete, Hanno B. Richards, Sibylle Haemmerle, Atul Deodhar   +14 more
doaj   +1 more source

Two Minimal Clinically Important Difference (2MCID) : A New Twist on an Old Concept [PDF]

, 2018
This work is open access licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, https://creativecommons.org/licenses/by-nc/4.0/Peer ...
Ali, Faraz M, Finlay, Andrew, Salek, M Sam   +2 more
core   +5 more sources

Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort

Advances in Rheumatology, 2023
Background Secukinumab has shown high efficacy in randomized controlled trials in both ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Here, we investigated its real-life effectiveness and tolerability in a cohort of AS and PsA patients ...
F. Molica Colella, G. Zizzo, V. Parrino, Maria Teresa Filosa, R. Cavaliere, F. Fazio, A. M. Molica Colella, A. Mazzone   +7 more
semanticscholar   +1 more source

Paradoxical pustular psoriasis in a patient with spondyloarthritis treated with secukinumab

JEADV Clinical Practice, 2023
Secukinumab is a monoclonal antibody used to specifically inhibit pathologic interleukin‐17 and therefore effectively manage conditions like plaque psoriasis, psoriatic arthritis and ankylosing spondylitis. Although we know that antitumor necrosis factor
Daniela Anghel, Mihaela Georgescu, Marcela Poenaru, Diana Maria Orleanu, George Sorin Tiplica   +4 more
doaj   +1 more source

A Review of Ankylosing Spondylitis [PDF]

, 2017
Ankylosing spondylitis (AS) is a systemic autoimmune disorder that induces ankylosis of the spine (fusion of the vertebrae at their various joints) and inflammatory arthritis of peripheral joints among other symptoms.
Owen, Hannah L
core   +1 more source